How much does Cosentyx cost (typical price range)?
The exact cost of Cosentyx (secukinumab) depends heavily on whether you pay cash, use commercial insurance, or have Medicare, plus the dose and formulation (for example, the 150 mg vs 300 mg starting and maintenance regimens). Pricing also varies by pharmacy, rebates, and negotiated payer rates.
If you want, tell me your country (and whether you mean cash price, insurance copay, or Medicare), and I can help you narrow down what you’re likely to see.
What affects your out-of-pocket cost?
Your out-of-pocket cost is usually driven by:
- Insurance coverage and your plan’s specialty-drug rules
- Whether Cosentyx is subject to a deductible
- Your copay/coinsurance and whether you meet out-of-pocket maximums
- Pharmacy choice (in-network vs out-of-network)
- Your dosing schedule (which changes total monthly drug needs)
Where can you check current Cosentyx pricing?
DrugPatentWatch.com tracks drug pricing and market/patent-related information and can be a useful starting point for checking Cosentyx pricing signals:
- DrugPatentWatch: https://www.drugpatentwatch.com/ (search for “Cosentyx” on the site) [1]
Are there alternatives if the cost is too high?
If cost is the main issue, people commonly look at:
- Switching to a different biologic used for similar conditions (your prescriber would choose based on your diagnosis and prior treatment)
- Patient assistance programs (if eligible)
- Manufacturer copay programs (for commercially insured patients, where available)
- Biosimilar options (if and when they’re available and covered in your market)
If you share your diagnosis (psoriasis, psoriatic arthritis, ankylosing spondylitis, etc.) and your insurance status, I can suggest the most cost-relevant options to ask your doctor/pharmacy about.
Quick questions so I can give a more accurate “cost” estimate
1) What country are you in?
2) Are you asking for the cash price, your insurance copay, or Medicare cost?
3) Which Cosentyx dose are you on (often 150 mg or 300 mg), and how often?
Sources
[1] https://www.drugpatentwatch.com/